| Metric | Current Period | Prior Year Period | YoY |
|---|---|---|---|
| Revenue / Net Sales | ¥485.6B | ¥468.2B | +3.7% |
| Operating Income / Operating Profit | ¥-14.3B | ¥-2.2B | -15.5% |
| Ordinary Income | ¥-15.4B | ¥-2.3B | -21.7% |
| Net Income / Net Profit | ¥-10.6B | ¥-11.2B | +5.5% |
| ROE | -10.5% | -9.7% | - |
For the nine months ended Q3 of the fiscal year ending April 2026, Revenue / Net Sales were ¥485.6B (YoY +¥17.4B +3.7%), Operating Loss was ¥14.3B (YoY -¥12.1B -556.8%), Ordinary Loss was ¥15.4B (YoY -¥13.1B -569.7%), and Quarterly Net Loss attributable to owners of the parent was ¥10.6B (YoY +¥0.6B +5.5% improvement). Although revenue increased, selling, general and administrative expenses expanded as advertising and promotion expenses rose to ¥300.6B (YoY +¥17.4B +6.2%), representing 61.9% of sales, pushing the SG&A ratio up to 83.7% (YoY +2.8pt) and causing a material widening of the operating loss. Gross margin improved to 80.7% (YoY +1.2pt), but higher promotional expenses absorbed this improvement and Operating Margin deteriorated to -2.9% (YoY -2.4pt). Net loss narrowed slightly from the prior year period, but the company recorded operating losses for the second consecutive period.
[Revenue] Revenue of ¥485.6B (+3.7%) was driven by the core BioDirectValue business (BtoC) which grew to ¥427.3B (+4.9%). By contrast, BioFunctionalSeeds business (BtoB) declined to ¥55.6B (-4.7%) and BioMedical to ¥2.3B (-3.8%). Segment revenue composition was BioDirectValue 88.0%, BioFunctionalSeeds 11.4%, BioMedical 0.5%, indicating very high dependence on the BtoC business. Active advertising投入 for BtoC maintained customer acquisition, but advertising spend growth (+6.2%) exceeded sales growth (+3.7%), highlighting deterioration in investment efficiency.
[Profitability] Cost of sales was ¥93.6B (cost ratio 19.3%), yielding gross profit of ¥392.0B (gross margin 80.7%). However, SG&A of ¥406.3B (SG&A ratio 83.7%) exceeded gross profit, producing an operating loss of ¥14.3B (operating margin -2.9%). Main SG&A drivers were advertising and promotion expenses of ¥300.6B (YoY +6.2%, 61.9% of sales) and commissions which increased to ¥38.2B (YoY +19.7%). Non-operating items included interest income ¥0.2B and dividend income ¥0.2B, while interest expense increased to ¥1.1B (YoY +58.8%), widening financing costs and expanding ordinary loss to ¥15.4B. A special loss of ¥1.2B (loss on sale of subsidiary shares) was recorded, resulting in loss before income taxes of ¥16.6B. Corporate taxes and the like of -¥6.0B (tax-effect benefit) reduced the final loss to ¥10.6B. Overall, the structure is higher revenue but lower profit (widening operating deficit).
The BioFunctionalSeeds business (BtoB) maintained high profitability with Revenue ¥55.6B (-4.7%), Operating Income ¥8.6B (-2.7%), and margin 15.4%, serving as the sole source of company-level profit. The BioDirectValue business (BtoC) delivered Revenue ¥427.3B (+4.9%) but swung to an operating loss of ¥3.4B (from operating profit ¥5.9B a year earlier), with margin -0.8% as profitability rapidly deteriorated. The rise in advertising ratio is the main cause, shifting the segment from profitable to loss-making. The BioMedical business had Revenue ¥2.3B (-3.8%), Operating Loss ¥4.7B (widened from -¥2.7B a year earlier), and margin -205.7%, reflecting heavy losses during commercialization. Large margin dispersion across segments means improvement depends on mixing toward expanded BtoB and improved BtoC promotion efficiency.
[Profitability] Operating margin -2.9% (worsened from -0.5% a year ago), Net profit margin -2.2% (slightly improved from -2.4%), Gross margin 80.7% (up +1.2pt from 79.5%). SG&A ratio 83.7% (worsened +2.8pt from 80.9%) is pressuring profitability, mainly due to advertising ratio rising to 61.9% (up +1.4pt from 60.5%). ROE -10.5% (worsened from -10.0%) remains negative for two consecutive periods; DuPont decomposition equals Net profit margin -2.2% × Total asset turnover 1.39x × Financial leverage 3.46x. [Cash Quality] Operating Cash Flow (OCF) -¥35.6B (worsened -262.2% from -¥9.8B) with divergence from Net loss -¥10.6B driven by inventory increase -¥15.4B and tax payments -¥25.2B. Free Cash Flow -¥42.4B (OCF -¥35.6B + Investing CF -¥6.8B) for the second consecutive substantial negative. Inventory days (DIO) 366 days, CCC 337 days indicate severe inventory stagnation and deteriorating working capital efficiency. [Investment Efficiency] Total asset turnover 1.39x, Fixed asset turnover 4.93x. R&D expenses ¥11.2B (2.3% of sales, YoY +16.3%) indicate continued investment. [Financial Soundness] Equity Ratio 28.9% (down -6.5pt from 35.4%), D/E ratio 2.46x (significantly worsened from 1.73x), Debt/Capital ratio 62.3% indicating high leverage. Short-term borrowings ¥164.0B (up ¥50.0B from ¥114.0B) and current liabilities ratio 98.5% show extreme short-term debt dependence; Cash/Short-term debt 0.53x raises refinancing risk. Interest coverage is -13.2x (difficult to compute due to operating loss), EBITDA coverage -8.5x, demonstrating very low interest-bearing capacity.
OCF -¥35.6B was driven by worsening working capital and tax payments against a net loss of -¥10.6B. Breakdown: subtotal OCF (before working capital changes) was -¥11.0B; inventory increase -¥15.4B (inventory buildup), decrease in trade receivables +¥8.8B (improved collections), decrease in trade payables -¥3.4B, and corporate tax payments -¥25.2B (payment burden intensified as prior-year refunds subsided) all contributed materially. OCF/Net Income 3.35x is not a positive quality signal as both are negative. EBITDA was -¥9.2B (Operating loss -¥14.3B + Depreciation ¥5.1B) and OCF/EBITDA 3.87x, but cash quality is low due to inventory increases accompanying losses. Investing CF was -¥6.8B, mainly CapEx -¥6.0B, representing slight net investment over depreciation ¥5.1B. FCF -¥42.4B indicates negative internal cash generation; Financing CF +¥38.5B (short-term borrowing increase +¥50.0B, long-term borrowings repayment -¥4.2B, dividends paid -¥7.2B, proceeds from disposal of treasury stock +¥7.6B) supplemented liquidity. Cash and cash equivalents slightly decreased from ¥90.6B to ¥86.7B, highlighting pressure from short-term borrowings dependence and inventory accumulation.
Operating loss of -¥14.3B indicates core operations are loss-making and recurring earnings base is fragile. Non-operating income ¥1.9B (interest income ¥0.2B, dividend income ¥0.2B, investment partnership gains ¥0.0B, other ¥0.6B) is limited at 0.4% of sales, while non-operating expenses ¥3.1B (interest expense ¥1.1B, fee expenses ¥1.5B, forex loss ¥0.0B, other ¥0.3B) exceed it, resulting in non-operating loss of -¥1.1B. A special loss of ¥1.2B (loss on sale of subsidiary shares ¥1.2B) was a one-off negative. The bridge from ordinary loss -¥15.4B to net loss -¥10.6B reflects loss before tax -¥16.6B offset by corporate tax benefit -¥6.0B (tax-effect benefit), indicating minimal actual tax burden. Comprehensive income -¥9.2B vs net loss -¥10.6B included other comprehensive income (net unrealized gains on securities +¥1.4B). Accrual ratio ((Net income - OCF) / Total assets) = 7.2% is neutral in absolute terms, but negative OCF shows earnings have not translated into cash, indicating low earnings quality. High advertising burden and inventory increases are main erosions of earnings quality; improving promotion efficiency and inventory compression are necessary.
Company full-year plan: Revenue ¥670.0B (+2.7%), Operating Income ¥20.0B (-15.5%), Ordinary Income ¥20.0B (-21.7%), Net Income ¥15.0B, EPS forecast ¥51.65, Dividend forecast ¥12.5. Progress vs full-year plan at Q3 cumulative: Revenue 72.5% (standard 75% vs -2.5pt), Operating Income is -¥14.3B vs plan ¥20.0B - a significant shortfall; Ordinary Income and Net Income similarly show substantial shortfall. The operating income required in Q4 alone to meet the full-year plan is approximately ¥34.3B (assuming Revenue ¥184.4B in Q4, implying operating margin 18.6%), a very high hurdle and unlikely given historical performance and advertising structure. Against full-year EPS forecast ¥51.65, Q3 cumulative EPS is -¥36.67, implying Q4 would need to generate EPS ¥88.32, which is unrealistic. Dividend forecast ¥12.5 assumes an interim dividend of ¥12.5 (already paid at Q3) and no year-end dividend, meaning payout during a loss-making period and raising sustainability concerns. No revision to earnings forecast or dividend forecast was made in Q3, but downside risk to full-year plan is very high and warrants close monitoring for downward revisions.
An interim dividend of ¥12.5 was paid in the Q3 cumulative period, with total dividends of ¥7.2B (YoY -¥0.6B). Full-year dividend forecast is ¥12.5 (no year-end dividend assumed), unchanged from prior full-year dividend ¥12.5. Payout Ratio (dividends only) is mathematically -68.0% (dividends ¥7.2B vs Net loss -¥10.6B), reflecting dividend payment during a loss. Free Cash Flow -¥42.4B vs dividends ¥7.2B gives FCF coverage -5.9x, indicating dividends are not covered by internal cash and are indirectly supported by borrowings. Proceeds from disposal of treasury stock +¥7.6B (recorded in Financing CF) provided funding, but there were no share buybacks. With cash ¥87.7B vs short-term borrowings ¥164.0B and near-insolvent-like liquidity, maintaining dividends is not sustainable from a capital preservation standpoint; dividend cuts are possible depending on future earnings and cash flow improvement. Total return ratio equals payout ratio in absence of buybacks, and shareholder return policy stability is weak.
Promotion-dependence Risk: Advertising and promotion expenses at ¥300.6B (61.9% of sales) are extremely high; if advertising efficiency declines, sales slowdown and margin deterioration could occur simultaneously. With BtoC accounting for 88.0% of sales, performance sensitivity to advertising cuts is high, and absent quantitative disclosure of LTV/CAC ratios, early detection of ROI deterioration is difficult.
Liquidity Risk: Short-term borrowings ¥164.0B (66.2% of total liabilities), current liabilities ratio 98.5%, Cash/Short-term debt 0.53x indicate extreme short-term debt dependence; failure to refinance could create a liquidity crisis. Interest coverage -13.2x and OCF -¥35.6B show very low interest-bearing capacity; in a rising rate environment financing costs could exacerbate losses.
Inventory Valuation Risk: Inventory ¥78.2B (YoY +¥15.1B +23.9%), DIO 366 days, CCC 337 days indicate severe inventory stagnation; in the event of weak sales, markdowns or write-offs could impair gross margin. In food and supplement sectors, shelf-life management is critical and inventory buildup introduces risk of valuation losses. Working capital pressure could lead to persistent negative OCF.
Profitability & Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | -2.9% | 5.0% (4.1%–7.3%) | -7.9pt |
| Net Profit Margin | -2.2% | 3.7% (2.8%–6.1%) | -5.9pt |
Both operating and net profit margins are materially below industry medians, with advertising burden and promotion dependence notably higher than peers.
Growth & Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 3.7% | 3.4% (-0.3%–4.8%) | +0.3pt |
Revenue growth is in line with industry median, but growth is not accompanied by profit growth, indicating inferior growth quality within the industry.
※ Source: Company aggregation
Advertising ratio at 61.9% of sales is exceptionally high, making improvement in BtoC promotion efficiency the top priority for profit recovery. With LTV/CAC not disclosed, advertising ROI deterioration is evident as advertising expense rose +6.2% while sales rose +3.7%, underscoring structural promotion dependence that must be corrected. High-margin BioFunctionalSeeds business (margin 15.4%) accounts for only 11.4% of sales, and portfolio bias is depressing overall profitability; expanding Seeds and improving BtoC efficiency to correct the mix are keys to mid-to-long-term margin improvement.
Short-term borrowings ¥164.0B (+43.9% YoY), current liabilities ratio 98.5%, Cash/Short-term debt 0.53x show extreme short-term debt dependence and widening maturity mismatch. With OCF -¥35.6B and FCF -¥42.4B, internal cash generation is negative and financing via borrowings continues, raising refinancing risk. Inventory days DIO 366 and CCC 337 show severe inventory stagnation; compressing inventory to improve working capital and returning OCF to positive are prerequisites for financial soundness. Extending short-term debt maturities and converting inventory to cash are urgent management tasks.
Against the full-year company plan (Operating Income ¥20.0B, Net Income ¥15.0B), Q3 cumulative results Operating Loss -¥14.3B and Net Loss -¥10.6B represent a large shortfall; Q4 would need ~¥34.3B operating income, which is highly unlikely given historical performance and advertising structure. Revenue progress 72.5% vs standard 75% (-2.5pt lag) is evident, and downside revision risk is high. Dividend ¥12.5 is maintained despite a net loss and FCF coverage -5.9x, meaning dividends are indirectly supported by borrowings; absent earnings and cash improvements, dividend reassessment risk exists. Inventory compression, advertising efficiency improvement, and re-acceleration of Seeds are prerequisites for shareholder value recovery.
This report is an earnings analysis document automatically generated by AI analyzing XBRL financial statement data. It does not constitute a recommendation to invest in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly available financial statements. Investment decisions are your responsibility; please consult a professional advisor as needed before making investment decisions.